Pharmaceuticals

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

Organon expands its Women's Health Accelerator to META, aiming to close health gaps and unlock a potential £1 trillion economic boost through digital innovation.

A new AI-driven approach to cancer therapy promises to breach the blood-brain barrier, offering hope for treating aggressive tumors where others have failed.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

A new partnership between Southern Research and Pathogenus Consulting combines US labs with a European network to fast-track treatments for global health threats.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

A new partnership aims to slash waste and streamline clinical trials, heralding a tech-driven transformation in the backbone of drug development.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.